Further enhancing the strategy for combating resistance, multifunctional lipid-based nanoparticles for the co-delivery of anticancer drugs and siRNA targeting EGFR mutations in NSCLC were developed to contain nanostructured lipid carriers loaded with gefitinib, paclitaxel, and siRNA. Here, EGFR is linked to non-small cell lung carcinoma.